Purple Biotech (PPBT) Change in Account Payables (2014 - 2026)

Purple Biotech (PPBT) reported Change in Account Payables of -$1.2 million for Q1 2026, down 109.97% year-over-year from $12.5 million in Q1 2025, and down 109.97% on a QoQ basis from -$592000.0 in Q1 2025.

Purple Biotech (PPBT) has 2 years of Change in Account Payables data on file, last reported at -$1.2 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -3.26 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 35.60 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Purple Biotech 3.58 Bn 3.57 Bn - -1.24 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -1.24 Mn
Mar 31, 2026 -1.24 Mn
Dec 31, 2025 1.29 Mn
Dec 31, 2025 1.29 Mn
Sep 30, 2025 -22,000.00
Sep 30, 2025 -22,000.00
Jun 30, 2025 -229,000.00
Jun 30, 2025 -229,000.00
Mar 31, 2025 -592,000.00
Mar 31, 2025 -592,000.00
Dec 31, 2024 -448,000.00
Dec 31, 2024 -448,000.00
Sep 30, 2024 -1.14 Mn
Sep 30, 2024 -1.14 Mn
Jun 30, 2024 -444,000.00
Jun 30, 2024 -444,000.00
Mar 31, 2024 -46,000.00
Mar 31, 2024 -46,000.00
Dec 31, 2023 919,000.00
Dec 31, 2023 919,000.00
Mar 31, 2023 250,000.00
Mar 31, 2023 250,000.00
Dec 31, 2022 -735,000.00
Dec 31, 2022 -735,000.00
Mar 31, 2022 173,000.00
Mar 31, 2022 173,000.00
Dec 31, 2021 -275,000.00
Dec 31, 2021 -275,000.00
Mar 31, 2021 171,000.00
Mar 31, 2021 171,000.00
Dec 31, 2020 32,000.00
Dec 31, 2020 32,000.00
Dec 31, 2019 361,000.00
Dec 31, 2019 361,000.00
Dec 31, 2018 -132,000.00
Dec 31, 2018 -132,000.00
Dec 31, 2017 -251,000.00
Dec 31, 2017 -251,000.00
Sep 30, 2015 321,000.00
Sep 30, 2015 321,000.00
Dec 31, 2014 500,000.00
Dec 31, 2014 500,000.00
Sep 30, 2014 474,000.00
Sep 30, 2014 474,000.00